The money men have moved in on a new technique for editing the human genome that promises to revolutionise the way many human diseases will be treated in the future. But Big Money has in the process divided a scientific community into two competing camps. <br /> <br />Some might see it has healthy scientific rivalry spilling over into commercial competition which could ultimately speed up medical innovation. But behind closed doors there is a desperate race to establish scientific and commercial priority over what could be the scientific discovery – and intellectual property – of the decade.
